Source comparison
TB-500 Fibrosis Reduction: Comparison of Tissue Types
Tendon/Ligament 12–16 weeks 6–8 weeks Low vascularity, minimal baseline MMP activity Slowest responder. Requires mechanical loading to see structural change Muscle/Fascia 6–10 weeks 3–4 weeks Adhesion density, surgical vs traumatic origin Responds well with co
This comparison does not assign a generated winner or score.
- Tendon/Ligament
- 12–16 weeks
- 6–8 weeks
- Low vascularity, minimal baseline MMP activity
- Slowest responder. Requires mechanical loading to see structural change
- Muscle/Fascia
- 6–10 weeks
- 3–4 weeks
- Adhesion density, surgical vs traumatic origin
- Responds well with consistent dosing and range-of-motion work
- Cardiac Tissue
- 16–24 weeks
- 8–10 weeks
- Three-dimensional fibrotic architecture
- Requires sustained dosing. Interim improvements are minimal
- Hepatic Tissue
- 18–24 weeks
- 10–12 weeks
- Cirrhotic vs non-cirrhotic baseline
- Best outcomes in early-stage fibrosis (F1–F2), limited effect in cirrhosis (F4)
- Dermal Scars
- 8–12 weeks
- 4–6 weeks
- Scar age, keloid vs hypertrophic phenotype
- Variable. Keloids show resistance due to excessive TGF-β1 activity